Method for diagnosing and distinguishing stroke and diagnostic devices for use therein
View Patent ↗A method for determining whether a subject has had a stroke and, if so, the type of stroke which includes analyzing the subject's body fluid for at least four selected markers of stroke, namely, myelin basic protein, S100 protein, neuronal specific enolase and a brain endothelial membrane protein such as thrombomodulin or a similar molecule. The data obtained from the analyses provide information as to the type of stroke, the onset of occurrence and the extent of brain damage and allow a physician to determine quickly the type of treatment required by the subject.
1. A method for diagnosing stroke and determining the evolution of occurrence thereof comprising:
a) analyzing a body fluid of a patient to detect the presence and concentration level of a first ischemic marker and a second ischemic marker, wherein each of said first and second ischemic markers is a specific glial marker, a specific neuronal marker or a specific axonal marker;
b) analyzing the body fluid of said patient to detect the presence and concentration level of a brain endothelial cell membrane protein; and
c) from the information obtained from said analyses, verifying the occurrence of stroke and determining whether the stroke is evolving in severity or subsiding.
2. A method according to claim 1 , wherein said specific glial marker is selected from the group consisting of the Beta Isoform of S100, Growth Associated Protein 43, Glutamine Synthetase, Glial Fibrillary Protein, Glycine Transporter 1, and Glycine Transporter 2.
3. A method according to claim 2 , wherein said specific glial marker is the Beta Isoform of S100.
4. A method according to claim 1 , wherein said specific neuronal marker is selected from the group consisting of Neuron Specific Enolase, Neuron Specific Glycoprotein, Caplain, Neurofibrillary Protein, Heat Shock Protein 72, and Beta Amyloid Precursor Protein.
5. A method according to claim 4 , wherein said specific neuronal marker is Neuron Specific Enolase.
6. A method according to claim 1 , wherein said specific axonal marker is selected from the group consisting of Myelin Basic Protein, Calbindin D-28K, Proteolipid Protein, Myelin Associated Glycoprotein and Neurofilament H.
7. A method according to claim 6 , wherein said specific axonal marker is Myelin Basic Protein.
8. A method according to claim 1 , wherein said brain endothelial cell membrane protein is selected from the group consisting of Thrombomodulin, Glucose Transporter 1 in the dimeric or tetrameric form, NeurothelinHT7, Gamma Glutamyl Transpeptidase and Pglycoprotein.
9. A method according to claim 8 , wherein said brain endothelial cell membrane protein is Thrombomodulin.
10. A method according to claim 1 , wherein said first ischemic marker is a specific glial marker and said second ischemic marker is a specific axonal marker.
11. A method according to claim 10 , wherein said specific glial marker is selected from the group consisting of the Beta Isoform of S100, Growth Associated Protein 43, Glutamine Synthetase, Glial Fibrillary Protein, Glycine Transporter 1, and Glycine Transporter 2.
12. A method according to claim 11 , wherein said specific axonal marker is selected from the group consisting of Myelin Basic Protein, Calbindin D-28K, Proteolipid Protein, Myelin Associated Glycoprotein and Neurofilament H.
13. A method according to claim 12 , wherein said specific glial marker is the Beta Isoform of S100.
14. A method according to claim 13 , wherein said specific axonal marker is Myelin Basic Protein.
15. A method according to claim 14 , wherein said brain endothelial cell membrane protein is selected from the group consisting of Thrombomodulin, Glucose Transporter 1 in the dimeric or tetrameric form, NeurothelinHT7, Gamma Glutamyl Transpeptidase and P-glycoprotein.
16. A method according to claim 14 , wherein said brain endothelial cell membrane protein is Thrombomodulin.
17. A method according to claim 1 , further comprising obtaining a second sample of body fluid from said patient and analyzing said sample to detect the presence and concentration of said first ischemic marker and said second ischemic marker, and determining whether said stroke is evolving in severity or subsiding.
18. A method according to claim 17 , wherein said second sample of body fluid is obtained at least 30 minutes after said first sample of body fluid is obtained.
19. A method according to claim 17 , wherein said second sample of body fluid is obtained at least 120 minutes after said first sample of body fluid is obtained.
20. A method according to claim 17 , wherein said second sample of body fluid is obtained at least 180 minutes after said first sample of body fluid is obtained.